Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

93.93EUR
20 Oct 2017
Change (% chg)

-- (--)
Prev Close
€93.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
520,790
52-wk High
€115.20
52-wk Low
€90.00

Chart for

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.01
Market Cap(Mil.): €12,139.72
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.28

Financials

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

German stocks - Factors to watch on October 4

FRANKFURT, Oct 4 The following are some of the factors that may move German stocks on Wednesday:

Oct 04 2017

Police search Merck KGaA's French plant in thyroid pill inquiry

LYON, France French police searched German drugmaker Merck KGaA's plant in Lyon on Tuesday as part of an investigation into complaints by patients about changes to its thyroid drug Levothyrox, a company spokeswoman said.

Oct 03 2017

REFILE-Police search Merck KGaA's French plant in thyroid pill inquiry

LYON, France, Oct 3 French police searched German drugmaker Merck KGaA's plant in Lyon on Tuesday as part of an investigation into complaints by patients about changes to its thyroid drug Levothyrox, a company spokeswoman said.

Oct 03 2017

Merck KGaA CFO: 2017 profit guidance 'damn challenging'

FRANKFURT Germany's Merck KGaA said it expected to meet its 2017 guidance, but warned it wouldn't be easy due to headwinds from currency fluctuations and a tough liquid crystals business.

Sep 28 2017

Merck KGaA eyes up to 700 million euro Mavenclad sales in EU

FRANKFURT Germany's Merck KGaA is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros ($823 million) in the European Union.

Sep 28 2017

Merck KGaA CFO: 2017 profit guidance "damn challenging"

FRANKFURT, Sept 28 Germany's Merck KGaA said it expected to meet its 2017 guidance, but warned it wouldn't be easy due to headwinds from currency fluctuations and a tough liquid crystals business.

Sep 28 2017

BRIEF-Merck KGaA says 2017 guidance range achievable, but challenging

* CFO says we still believe we will make our 2017 guidance range, but it is very challenging

Sep 28 2017

Merck KGaA eyes up to 700 mln eur Mavenclad sales in EU

FRANKFURT, Sept 28 Germany's Merck KGaA is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros ($823 million) in the European Union.

Sep 28 2017

BRIEF-Merck KGAA appoints Paolo Carli head of Middle East, Africa & Turkey for healthcare business‍​

* Merck KGAA - announced appointment of Paolo Carli as head of Middle East, Africa & Turkey (MEA) region for its healthcare business‍​ Source text: (http://bit.ly/2htYmpk) Further company coverage:

Sep 25 2017

Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod

FRANKFURT European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.

Sep 21 2017

Earnings vs. Estimates